ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Merck, Novartis and NovoCure side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Merck×Novartis×NovoCure×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

MerckNovartisNovoCure
studies on the registry2,4533,90028
open to participants now1452113
phase 3 studies under way112942
reach primary completion within a year601250
programswith a study of their own in two years8477+7 named onlynone read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMerckNovartisNovoCure
Phase 1

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
–
Phase 223%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. arumakimigphase 2
  4. QCZ484phase 2
  5. DDY391phase 2

and 30 more — sign in to see them all

45%
–
Phase 3

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
–
Approved, new studies

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%
–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Merck25 readouts · 6 phase 3

Merck, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. pembrolizumabapproved, new study · Nov 20 · NCT04634877

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
NovoCure0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 5

  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

NovoCure

No programs read for this company.

Where they overlap

Conditions where at least two of them have programs: 39 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionMerckNovartisNovoCure
Neoplasms2 of 3 · compare here

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Novartis in Neoplasms: 2 programs

  1. tulmimetostatphase 2
  2. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

–
Carcinoma, Non-Small-Cell Lung2 of 3 · compare here

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

–
Prostatic Neoplasms2 of 3 · compare here

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

–
Breast Neoplasms2 of 3 · compare here

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

–
Renal Insufficiency2 of 3 · compare here

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

–
Small Cell Lung Carcinoma2 of 3 · compare here

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

–
Arthritis, Rheumatoid2 of 3 · compare here

Merck in Arthritis, Rheumatoid: 1 program

  1. MK-8690phase 2

Their studies: Merck’s studies of Arthritis, Rheumatoid in search

Novartis in Arthritis, Rheumatoid: 5 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  4. DKB903phase 1
  5. secukinumabapproved, new study

Their studies: Novartis’s studies of Arthritis, Rheumatoid in search

–
Alzheimer Disease2 of 3 · compare here

Merck in Alzheimer Disease: 3 programs

  1. MK-2214phase 2
  2. BCG Vaccinephase 2
  3. MK-1167phase 2

Their studies: Merck’s studies of Alzheimer Disease in search

Novartis in Alzheimer Disease: 2 programs

  1. Oligonucleotides, Antisensephase 2
  2. VHB937phase 2

Their studies: Novartis’s studies of Alzheimer Disease in search

–
Carcinoma, Renal Cell2 of 3 · compare here

Merck in Carcinoma, Renal Cell: 4 programs

  1. belzutifanphase 3
  2. intismeran autogenephase 3
  3. raludotatug deruxtecanphase 3
  4. zanzalintinibphase 3

Their studies: Merck’s studies of Carcinoma, Renal Cell in search

Novartis in Carcinoma, Renal Cell: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Carcinoma, Renal Cell in search

–
Dermatitis, Atopic2 of 3 · compare here

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

–
Hypercholesterolemia2 of 3 · compare here

Merck in Hypercholesterolemia: 3 programs

  1. enlicitide decanoatephase 3
  2. enlicitide chloridephase 3
  3. rosuvastatinphase 3

Their studies: Merck’s studies of Hypercholesterolemia in search

Novartis in Hypercholesterolemia: 2 programs

  1. QCZ484phase 2
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Hypercholesterolemia in search

–
Malaria, Falciparum2 of 3 · compare here

Merck in Malaria, Falciparum: 1 program

  1. pyronaridinephase 1

Their studies: Merck’s studies of Malaria, Falciparum in search

Novartis in Malaria, Falciparum: 4 programs

  1. ganaplacidephase 3
  2. cipargaminphase 2
  3. INE963phase 2
  4. ganaplacidephase 2

Their studies: Novartis’s studies of Malaria, Falciparum in search

–

Show all 39

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Merck 40 of 84 · Novartis 56 of 77 · NovoCure 0 of 0 programs (29 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Novartis: 7).